Huimei Capital

Huimei Capital is a venture capital firm investing in the medical and healthcare ecosystem, founded by Hillhouse Capital and Mayo Clinic. The firm primarily invests in early and growth-stage healthcare companies, aiming to build a professional investment platform with an international vision and local execution. Huimei Capital focuses on creating a sustainable and profitable healthcare ecosystem by supporting innovative firms in the sector.

The firm's investment strategy encompasses various sectors within the healthcare industry, including biopharmaceuticals, medical devices, and healthcare services. Huimei Capital seeks to invest in companies that demonstrate strong growth potential and align with its mission to enhance the quality and accessibility of healthcare. The firm is committed to leveraging its resources and network to support the development of transformative healthcare solutions.

Huimei Capital's portfolio includes investments in companies such as Osteal Therapeutics, a clinical-stage biopharmaceutical firm developing combination therapies for musculoskeletal infections. The firm has also invested in OncoC4, a developer of novel biologicals for cancer treatment, and KBP Biosciences, which develops and commercializes innovative small-molecule therapeutics for cardiorenal and infectious diseases. These investments reflect Huimei Capital's dedication to advancing healthcare through strategic partnerships and support for innovative companies in the sector.